Los Angeles, USA, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Global Soft Tissue Sarcoma Pipeline Analysis: A Vast Number of Pipeline Therapies Expected to Get Launched in the Next Decade
Analysis of 100+ pharmaceutical companies and 100+ emerging therapies in the Soft Tissue Sarcoma landscape
DelveInsight’s Soft Tissue Sarcoma Pipeline Insights report provides a holistic view of the pipeline therapies that are under development in pre-clinical as well as clinical stages of development, and growth prospects across the Soft Tissue Sarcoma domain.
The report lays down a complete coverage of the therapeutics by development stage, product type, route of administration, molecule type, and MOA type for Soft Tissue Sarcoma across the complete product development cycle, including all clinical and non-clinical stages.
The Soft Tissue Sarcoma pipeline report brings to the eye business opportunities, threats, prospective collaborations, strong competitors, growth strategies, failed as well as discontinued drugs.
Some of the key highlights of the Soft Tissue Sarcoma Pipeline report
- 100+ Key companies are actively engaged in the Soft Tissue Sarcoma market landscape.
- Key players that are developing the drugs for the treatment of Soft Tissue Sarcoma include NanoCarrier, Philogen, Lytix Biopharma, Karyopharm Therapeutics, Genentech, Nanobiotix, Boehringer Ingelheim, Eisai, Daiichi Sankyo, Hutchison MediPharma, Merck & Co, Incyte Corporation, Pfizer, Rafael Pharmaceuticals, NewVac, Hillstream BioPharma, Taiwan Liposome Company, Shanghai Junshi Biosciences, AstraZeneca, Monopar Therapeutics, Adaptimmune, GlaxoSmithKline, AVEO Oncology, Novartis, Kyowa Kirin, Macrogenics, Merrimack Pharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, Bristol-Myers Squibb, SYZ Cell Therapy, Presage Biosciences, Cebiotex, Cyteir Therapeutics, Apexigen, BioAtla, Guangdong Xiangxue Precision Medical among others.
- In December 2020, Moleculin Biotech announced that FDA granted an orphan drug designation to annamycin for soft tissue sarcoma.
- In October 2020, Rafael Pharmaceuticals announced that the FDA has granted an Orphan Drug designation to CPI-613 (devimistat) for the treatment of soft tissue sarcoma.
- In July 2019, Monopar Therapeutics and the Spanish Sarcoma Group announced that they have entered into a clinical collaboration agreement to conduct a Phase 2 clinical trial to evaluate Monopar's investigational drug Camsirubicin in patients with advanced soft tissue sarcoma (ASTS).
- In March 2019, Italian cancer startup Philogen got off an impressive $70M funding round.
Request for Sample @ Soft Tissue Sarcoma Pipeline Insights and Analysis for detailed report offerings
Soft Tissue Sarcoma Pipeline Therapies
LTX-315: Lytix Biopharma
LTX-315 (Ruxotemitide) is a potential candidate in the Soft tissue sarcoma pipeline owing to its ability to fully personalize immunotherapy by its mode of action to use the patient’s own tumor as its own vaccine, expose the immune system to one patient’s own cancer antigens, and generate patient-specific antitumor immunity. LTX-315 is the oncolytic peptide that kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization.
Lytix Biopharma is investigating the safety and efficacy of LTX-315 and adoptive T cell therapy in an open-label Phase II single-center study in patients with advanced/metastatic soft tissue sarcoma.
In August 2020, Verrica Pharmaceuticals entered into an exclusive worldwide license agreement with Lytix Biopharma to develop and commercialize LTX-315 for dermatologic oncology indications. Verrica intends to focus initially on basal cell and squamous cell carcinomas as the lead indications for development.
Selinexor: Karyopharm Therapeutics
Selinexor (KPT-330) is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound. Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus. This reinitiates and amplifies their tumor suppressor function and is believed to lead to the selective induction of apoptosis in cancer cells, while largely sparing normal cells. It is currently in Phase I of the clinical trial study.
CPI-613 (devimistat): Rafael Pharmaceuticals
CPI-613 is an experimental anti-mitochondrial agent that is currently under investigation in different tumors. Rafael Pharmaceuticals recently launched a phase 1/2 study to find the maximum tolerated dose (MTD) of CPI-613 in patients with relapsed/refractory soft tissue sarcoma and determine the efficacy and safety of the drug. In October 2020, FDA granted an Orphan Drug designation to CPI-613 (devimistat) for the treatment of soft tissue sarcoma.
HSB 114: Hillstream BioPharma
HSB-114 is a next-generation immunotherapeutic agent of a previously developed predecessor compound. Quatramer technology allows a proprietary TNF-alpha cDNA to be incorporated preferentially into tumor nuclei, hijacking cancer’s genome and tricking its machinery to make the powerful cytokine and destroy itself. HSB-114 can be injected intratumorally or given systemically for metastatic soft tissue sarcoma (mSTS).
For more detailed information revolving around drug profiles, contact @ Soft Tissue Sarcoma Pipeline Analysis
Soft Tissue Sarcoma Therapeutic Assessment
- By Product Type
- By Stage
- Discovery
- Pre-clinical
- Phase I
- Phase II
- Phase III
- Pre-registration
- By Route of Administration
- Oral
- Intravenous
- By Molecule Type
- Small Molecule
- Monoclonal Antibody
- Targets:
- Protease
- Immune System
- Multiple kinases
- By Mechanism of Action
- Programmed cell death-1 ligand-1 inhibitors
- Free radical stimulants
- Platelet-derived growth factor-alpha receptor antagonists
- Type II DNA topoisomerase inhibitors
-
- Monotherapy
- Combination Therapy
Key Soft Tissue Sarcoma Pipeline Therapies
- Fibromun (L19-TNF): Philogen
- LTX-315: Lytix Biopharma
- Selinexor: Karyopharm Therapeutics
- NC-6300: NanoCarrier
- TAEST16001: Guangdong Xiangxue Precision Medical
- Atezolizumab: Genentech
- Boehringer Ingelheim: Nintedanib
- Nanobiotix: NBTXR3
- Hutchison MediPharm: Surufatinib
- Incyte Corporation: Itacitinib
- Rafael Pharmaceuticals: CPI-613 (devimistat)
- NewVac: Quisinostat
- AROG Pharmaceuticals/Pfizer: Crenolanib
- Hillstream BioPharma: HSB 114
- Taiwan Liposome Company: TLC178
- Shanghai Junshi Biosciences: Toripalimab
- Monopar Therapeutics: Camsirubicin
- Adaptimmune: ADP-A2M4 program
- Guangdong Xiangxue Precision Medical: TAEST 16001
- Onxeo: PXD101
- AVEO Oncology/Kyowa Kirin: Tivozanib
- GlaxoSmithKline/Novartis: Pazopanib
- Merrimack Pharmaceuticals: MM-310
- Incyte Corporation/Macrogenics: Retifanlimab
- Loxo Oncology: LOXO-292
- SYZ Cell Therapy: Combination Product: MASCT-I, PD1 Antibody, Apatinib
- Chia Tai Tianqing Pharmaceutical Group: Anlotinib Hydrochloride
- Bristol-Myers Squibb: Trabectedin
- PharmaMar: lurbinectedin (PM01183)
- AstraZeneca: Durvalumab and Tremelimumab
- Cebiotex: CEB-01
- Cyteir Therapeutics: CYT-0851
- Apexigen: Doxorubicin and APX005M
- BioAtla: CAB-ROR2-ADC
Scope of the Soft Tissue Sarcoma Pipeline Insights Report
- Coverage: Global
- Major Players: 100+ Key Companies
- Prominent Players: Genentech, NanoCarrier, Philogen, Lytix Biopharma, Eisai, Hutchison MediPharma, Merck & Co, Incyte Corporation, Pfizer, Rafael Pharmaceuticals, NewVac, Hillstream BioPharma, Taiwan Liposome Company, Shanghai Junshi Biosciences, AstraZeneca, Monopar Therapeutics, Macrogenics, Merrimack Pharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, Bristol-Myers Squibb, SYZ Cell Therapy, Cebiotex, Cyteir Therapeutics, Apexigen, BioAtla, and others.
- Key Drugs Profiles: 100+ Products
Key Questions Answered in the Soft Tissue Sarcoma Pipeline Insights Report
- What are the current options for Soft Tissue Sarcoma treatment?
- How many companies are developing therapies for the treatment of Soft Tissue Sarcoma?
- What are the principal therapies developed by these companies in the industry?
- How many therapies are developed by each company for the treatment of Soft Tissue Sarcoma?
- How many Soft Tissue Sarcoma emerging therapies are in the early-stage, mid-stage, and late stages of development for the treatment of Soft Tissue Sarcoma?
- Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact the Soft Tissue Sarcoma market?
Got Queries? Get in touch with our Business Development Executive @ Soft Tissue Sarcoma Therapeutic Pipeline Development
Table of Contents
| 1 | Report Introduction |
| 2 | Soft Tissue Sarcoma |
| 3 | Soft Tissue Sarcoma Current Treatment Patterns |
| 4 | Soft Tissue Sarcoma - DelveInsight's Analytical Perspective |
| 5 | Therapeutic Assessment |
| 6 | Soft Tissue Sarcoma Late-Stage Products (Phase-III) |
| 7 | Soft Tissue Sarcoma Mid Stage Products (Phase-II) |
| 8 | Early-Stage Products (Phase-I) |
| 9 | Pre-clinical Products and Discovery Stage Products |
| 10 | Inactive Products |
| 11 | Dormant Products |
| 12 | Soft Tissue Sarcoma Discontinued Products |
| 13 | Soft Tissue Sarcoma Product Profiles |
| 14 | Soft Tissue Sarcoma Key Companies |
| 15 | Soft Tissue Sarcoma Key Products |
| 16 | Dormant and Discontinued Products |
| 17 | Soft Tissue Sarcoma Unmet Needs |
| 18 | Soft Tissue Sarcoma Future Perspectives |
| 19 | Soft Tissue Sarcoma Analyst Review |
| 20 | Appendix |
| 21 | Report Methodology |
Contact for more information about report offerings @ Soft Tissue Sarcoma Drug Pipeline Outlook
Visit for more such insights into Soft Tissue Sarcoma Domain
Related Reports:
DelveInsight’s ‘Soft Tissue Sarcoma (STS) with lung metastases—Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the STS with lung metastases, historical and forecasted epidemiology as well as the STS with lung metastases market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
DelveInsight's "Soft Tissue Neoplasms - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Soft Tissue Neoplasms, historical and forecasted epidemiology as well as the Soft Tissue Neoplasms market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Complicated Skin And Soft Tissue Infections Market
DelveInsight's "Complicated skin and soft tissue infections (cSSTI) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Complicated skin and soft tissue infections (cSSTI), historical and forecasted epidemiology as well as the Complicated skin and soft tissue infections (cSSTI) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
DelveInsight's "Ewing Sarcoma Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Ewing Sarcoma, historical and forecasted epidemiology as well as the Ewing Sarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
DelveInsight's "Kaposi's Sarcoma Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Kaposi's Sarcoma, historical and forecasted epidemiology as well as the Kaposi's Sarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
DelveInsight's "Synovial Sarcoma Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Synovial Sarcoma, historical and forecasted epidemiology as well as the Synovial Sarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
DelveInsight's "Uterine Sarcoma Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Uterine Sarcoma, historical and forecasted epidemiology as well as the Uterine Sarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
DelveInsight’s ‘Multiple Myeloma (MM)-Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the MM, historical and forecasted epidemiology as well as the MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), Japan and China.
Non-Small Cell Lung Cancer Market
DelveInsight’s ‘Non-Small Cell Lung Cancer (NSCLC) - Market Insights, Epidemiology, and Market Forecast - 2030’ report delivers an in-depth understanding of the Non-Small Cell Lung Cancer, historical and forecasted epidemiology as well as the Non-Small Cell Lung Cancer market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.
DelveInsight's "Prostate cancer Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Prostate cancer, historical and forecasted epidemiology as well as the Prostate cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.